Ciltacabtagene autoleucel (Carvykti)

Status:

Do Not Prescribe (DNP)

Decision Date:

March 2023

Comments

DNP: NICE TA889 - Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (Terminated Appraisal).

NHSE commissioned.

search again